Madrigal Pharmaceuticals Inc (MDGL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 958,403 | 180,133 | 0 | 0 | 0 |
| Cost of Goods | 56,148 | 6,233 | N/A | 0 | N/A |
| Gross Profit | 902,255 | 173,900 | N/A | N/A | N/A |
| Operating Expenses | 1,202,500 | 672,008 | 380,496 | 293,571 | 242,482 |
| Operating Income | -300,097 | -497,875 | -380,496 | -293,571 | -242,482 |
| Interest Expense | 22,309 | 14,671 | 12,712 | 3,964 | 0 |
| Other Income | 34,122 | 46,654 | 19,578 | 2,185 | 636 |
| Pre-tax Income | -288,284 | -465,892 | -373,630 | -295,350 | -241,846 |
| Net Income Continuous | -288,284 | -465,892 | -373,630 | -295,350 | -241,846 |
| Net Income | $-288,284 | $-465,892 | $-373,630 | $-295,350 | $-241,846 |
| EPS Basic Total Ops | -12.85 | -21.90 | -19.99 | -17.23 | -14.63 |
| EPS Basic Continuous Ops | -12.85 | -21.90 | -19.99 | -17.23 | -14.63 |
| EPS Diluted Total Ops | -12.85 | -21.90 | -19.99 | -17.23 | -14.63 |
| EPS Diluted Continuous Ops | -12.85 | -21.90 | -19.99 | -17.23 | -14.63 |
| EPS Diluted Before Non-Recurring Items | -12.85 | -21.90 | -19.99 | -17.23 | -14.63 |
| EBITDA(a) | $-293,777 | $-495,090 | $-377,555 | $-292,307 | $-242,077 |